Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03675308
Recruitment Status : Active, not recruiting
First Posted : September 18, 2018
Last Update Posted : May 12, 2020
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Biological: placebo for rizankizumab Biological: risankizumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 964 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Actual Study Start Date : March 25, 2019
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : July 4, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
Biological: placebo for rizankizumab
Placebo for risankizumab administered by subcutaneous (SC) injection

Biological: risankizumab
Risankizumab administered by subcutaneous (SC) injection
Other Names:
  • ABBV-066
  • BI 655066
  • SKYRIZI

Experimental: Risankizumab
Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
Biological: risankizumab
Risankizumab administered by subcutaneous (SC) injection
Other Names:
  • ABBV-066
  • BI 655066
  • SKYRIZI




Primary Outcome Measures :
  1. Percentage of Participants Achieving at least 20% Improvement in American College of Rheumatology (ACR20) at Week 24 [ Time Frame: Week 24 ]
    ACR20 is defined as at least 20% improvement in swollen joint count, tender joint count, and at least 3 out of the following 5 variables: 1) Patient's Assessment of psoriatic arthritis (PsA) Pain Intensity visual analog scale (VAS), 2) Patient's Global Assessment of Disease VAS, 3) Physician's Global Assessment of Disease Activity VAS, 4) Patient's Assessment of Disability on Health Assessment Questionnaire Disability Index (HAQ-DI), and 5) Serum high-sensitivity C-reactive protein (serum hs-CRP).


Secondary Outcome Measures :
  1. Change In Health Assessment Questionnaire-Disability Index (HAQ-DI) [ Time Frame: Week 24 ]
    The HAQ-DI is a self-reported questionnaire of how the patient's illness affects their ability to function in their daily life over the past week.

  2. Percentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response (In The Subset Of Participants With A Body Surface Area [BSA] >= 3% At Baseline) [ Time Frame: Week 24 ]
    PASI 90 denotes greater than or equal to 90% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity.

  3. Change in modified Total Sharp Score (PsA-mTSS) [ Time Frame: Week 24 ]
    The modified PsA-mTSS method is used to evaluate radiographic evidence of damage.

  4. Percentage of Participants Achieving Minimal Disease Activity (MDA) [ Time Frame: Week 24 ]
    The percentage of participants who achieve MDA.

  5. Change in Fingernail Psoriasis [ Time Frame: Week 24 ]
    Fingernail psoriasis will be evaluated using either the Physician Global Assessment - Fingernails (PGA-F) or the modified Nail Psoriasis Severity Index (mNAPSI), depending on location.

  6. Percentage Of Participants With Resolution Of Enthesitis (Leeds Enthesitis Index [LEI] = 0) In Participants with Enthesitis at Baseline [ Time Frame: Week 24 ]
    The LEI will be used to assess the presence or absence of enthesitis.

  7. Percentage Of Participants With Resolution Of Dactylitis (LDI = 0) In Participants With Dactylitis at Baseline [ Time Frame: Week 24 ]
    The LDI will be used to assess the presence or absence of dactylitis.

  8. Change In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) [ Time Frame: Week 24 ]
    The SF-36 is a 36-item, general health, self-administered questionnaire.

  9. Change In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire [ Time Frame: Week 24 ]
    The FACIT-Fatigue is a 13-item questionnaire that evaluates fatigue/tiredness and its impact on daily activities and functioning in chronic diseases.

  10. Percentage Of Participants Achieving ACR50 Response [ Time Frame: Week 24 ]
    ACR50 response is defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PhGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP).

  11. Percentage Of Participants Achieving ACR70 Response [ Time Frame: Week 24 ]
    ACR70 response is defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PhGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit.
  • Participant has active disease at Baseline
  • Diagnosis of active plaque psoriasis.
  • Participant has demonstrated an inadequate response or intolerance to conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).
  • Presence of either at Screening:

    • ≥ 1 erosion on radiograph as determined by central imaging review or;
    • High sensitivity C-Reactive Protein (hsCRP) ≥ 3.0 mg/L.

Exclusion Criteria:

  • Participant is considered by investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant has a known hypersensitivity to risankizumab.
  • Participant has previous treatment with biologic agent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03675308


Locations
Show Show 257 study locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
Additional Information:
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03675308    
Other Study ID Numbers: M16-011
2017-002465-22 ( EudraCT Number )
First Posted: September 18, 2018    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases